Coherus Oncology Inc (NASDAQ: CHRS) is -42.25% lower on its value in year-to-date trading and has touched a low of $0.66 and a high of $2.43 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CHRS stock was last observed hovering at around $0.78 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $0.80, the stock is -3.37% and -10.97% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing 1.92% at the moment leaves the stock -27.34% off its SMA200. CHRS registered -56.21% loss for a year compared to 6-month loss of -34.67%. The firm has a 50-day simple moving average (SMA 50) of $0.89522 and a 200-day simple moving average (SMA200) of $1.096875.
The stock witnessed a -21.86% gain in the last 1 month and extending the period to 3 months gives it a -22.62%, and is -0.26% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.52% over the week and 5.73% over the month.
Coherus Oncology Inc (CHRS) has around 228 employees, a market worth around $92.40M and $197.50M in sales. Profit margin for the company is -66.30%. Distance from 52-week low is 20.70% and -67.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-114.62%).
The EPS is expected to shrink by -626.69% this year
158.0 institutions hold shares in Coherus Oncology Inc (CHRS), with institutional investors hold 58.31% of the company’s shares. The shares outstanding are 115.91M, and float is at 111.42M with Short Float at 29.72%. Institutions hold 54.50% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 11.75 million shares valued at $$20.33 million. The investor’s holdings represent 10.2356 of the CHRS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 10.6 million shares valued at $$18.34 million to account for 9.2339 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 10.4 million shares representing 9.0577 and valued at over $$17.99 million, while TEMASEK HOLDINGS (PRIVATE) LTD holds 5.0678 of the shares totaling 5.82 million with a market value of $$10.07 million.
Coherus Oncology Inc (CHRS) Insider Activity
The most recent transaction is an insider sale by Wahlstrom Mats, the company’s Director. SEC filings show that Wahlstrom Mats sold 99,988 shares of the company’s common stock on May 23 ’25 at a price of $0.74 per share for a total of $73881.0. Following the sale, the insider now owns 0.0 shares.
